Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
VanEck Biotech ETF(BBH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BBH
10/28/2026: BBH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
The VanEck Biotech ETF (BBH) provides concentrated exposure to the U.S. biotechnology industry by tracking a market-cap-weighted index of major sector players. Its primary strength lies in its focused access to established large-cap biotech companies, managed by the reputable firm VanEck. It is best suited for growth-oriented investors who want thematic exposure but can withstand the inherent volatility and sector-specific risks like clinical trial outcomes and drug pricing legislation. Investors should monitor healthcare policy shifts and the innovation pipeline of the fund's top holdings as primary drivers of long-term performance.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The biotech sector offers significant long-term growth potential driven by innovation and aging global demographics. |
| Momentum investor | Strong fit while signal remains positive | Biotech stocks often move in strong, news-driven trends that suit momentum-based strategies. |
| Value investor | Mixed fit | Many biotech holdings are valued on future pipeline potential rather than current cash flow, making traditional value metrics less applicable. |
| Dividend/Income investor | Weak fit | The portfolio focuses on capital appreciation and innovation, typically offering very little in the way of dividend yield. |
| Low-risk investor | Weak fit | The biotechnology sector is characterized by high volatility and significant binary risk, which is unsuitable for low-risk portfolios. |
Investor Profile
Ideal Investor Profile
The ideal investor is one seeking targeted growth exposure to the biotech sector and who can tolerate high volatility.
Suitability
Best for long-term growth-oriented investors rather than active traders or those seeking stable income.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Biotech stocks are prone to sharp price swings based on clinical results and regulatory decisions. |
| Market risk | Medium / high | General market downturns often disproportionately impact high-beta sectors like biotechnology. |
| Concentration | High | The fund holds a smaller basket of securities compared to broader market indices, increasing sensitivity to individual company performance. |
| Tracking/expense | Low | The expense ratio is competitive and the fund reliably tracks its index. |
| Liquidity | Medium | While generally liquid, liquidity can tighten during sector-wide panics or negative news events. |
| Business/sector quality | Medium / high | Dependence on R&D success and regulatory approval creates a high-stakes business environment. |
Risk Analysis
Volatility
BBH experiences higher-than-average market volatility due to its narrow focus on the biotech sector.
Market Risk
The fund is heavily exposed to regulatory, clinical, and macro-economic risks specific to biotechnology.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | U.S. Biotechnology and Pharmaceutical Equities | 99 | This exposure provides direct access to the revenue and innovation cycles of leading biotech companies. |
| Cash/collateral | Cash and Cash Equivalents | 1 | Minimal cash is held for daily operational liquidity and portfolio rebalancing. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 69.2% | Avg. Invested days 89 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.